Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation (NCT06647459) | Clinical Trial Compass
TerminatedNot Applicable
Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation
Stopped: Grant proposal was sent to NIH 3 times but did not score well enough to receive funding
United States32 participantsStarted 2023-12-13
Plain-language summary
To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Adults aged 18 and older
✓. Diagnosed with AF before age 60
✓. Scheduled for catheter-based AF ablation (de-novo or repeat)
✓. Able to provide written, informed consent
✓. P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control.
Exclusion criteria
✕. Diagnosed with a genetic CM or arrhythmia syndrome prior to AF
✕. VUS in 'possibly pathogenic' subgroup (control group only)
✕. Pacemaker or ICD
✕. Previous PVC or VT ablation
✕. LVEF \<20%
✕. Prosthetic mitral or aortic valve
✕
What they're measuring
1
VT Inducibility
Timeframe: At the time of procedure
2
Presence of ventricular arrhythmias per specific site